1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

US FDA’s Breakthrough Designation Pace Slows, But Topics Broaden

 
• By Bridget Silverman

The 19 breakthrough therapy designations awarded so far this year run the gamut from areas that traditionally have not fared well with BTDs, like cardiovascular and respiratory disease, alongside the traditional cancer and orphan disease tentpoles.

Breakthrough slow down
The pace of designations for the fastest ways to get through FDA are slowing down. • Source: Nielsen Hobbs; the Pink Sheet| Shutterstock images

US FDA’s flagship expedited review programs – the breakthrough therapy designation and its younger cousin, the biologics-focused regenerative medicine advanced therapy designation – have added new designations at a slower pace than the peak a few years ago.

Those designations that have been announced this year, however, illustrate the widening scope of the programs beyond the oncologics and rare disease

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers